
News|Slideshows|March 25, 2019
ACC.19: 3 Studies in Cardioprotection
Author(s)Veronica Hackethal, MD
Dapagliflozin, icosapent ethyl, and bempedoic acid were found to reduce clinical or surrogate CV endpoints in studies presented at ACC.19, March 16-18, in New Orleans, LA.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
Pediatric Influenza Vaccination Linked to Fewer Diagnoses in Claims Study
2
FDA Issues Complete Response Letter for Cingulate ADHD Drug CTx-1301
3
FDA Approves Xocova as First Oral COVID-19 Postexposure Prophylaxis Option
4
Survey Finds Gaps in US Adult Awareness of HPV, Mpox STI Vaccine Prevention
5


















































































































































